Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades.

    ... BACKGROUND: Persistent neutropenia associated with severe aplastic anemia (SAA) is an ...

    Research Article last updated 10/11/2011 - 5:58pm.

  2. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.

    ... 3/4 non-hematologic adverse events included febrile neutropenia (22% of patients), other infection (11%), pulmonary (11%), ...

    Research Article last updated 10/01/2012 - 9:58am.

  3. Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis

    ... and 0.001, respectively). The incidences of grades 3-4 neutropenia , thrombocytopenia , leukopenia, anemia , deep ...

    Research Article last updated 11/28/2016 - 9:36am.

  4. Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes.

    ... supportive care (67%). Grade 3-4 anemia , neutropenia , and thrombocytopenia with AZA vs CCR were 13% vs 4%, ...

    Research Article last updated 10/11/2011 - 5:58pm.

  5. The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes.

    ... but with similar degrees of anemia and neutropenia , transfusion requirements, and similar incidences of ...

    Research Article last updated 06/20/2013 - 11:02am.

  6. Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes

    ... common grade 3-4 treatment-emergent adverse events were neutropenia (52%) and leukopenia (39%). Pharmacokinetic profiles were ...

    Research Article last updated 02/03/2017 - 10:05am.

  7. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia

    ... (12.2%), nausea (7.3%), vomiting (7.3%), febrile neutropenia (19.5%), and fatigue (9.8%). Azacitidine exposure increased ...

    Research Article last updated 10/11/2011 - 5:58pm.

  8. Treatment of low-risk myelodysplastic syndromes

    ... good efficacy, but raised some safety concern. Although neutropenia is targeted symptomatically with growth factor ...

    Research Article last updated 01/26/2017 - 10:42am.

  9. Promising news for older AML patients

    ... in 32% of those on the 800-mg dose. Grade 3/4 febrile neutropenia occurred in 48% and 30%, respectively, and neutropenia in 40% and 32%. A phase 3 study of venetoclax at the 400-mg ...

    Article last updated 07/19/2017 - 11:19am.

  10. 5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials

    ... grade 3-4 thrombocytopenia and 30% grade 3-4 neutropenia ). Our results suggest that advanced age should not preclude ...

    Research Article last updated 06/15/2012 - 2:13pm.